{"id":381502,"date":"2020-11-16T07:33:19","date_gmt":"2020-11-16T12:33:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381502"},"modified":"2020-11-16T07:33:19","modified_gmt":"2020-11-16T12:33:19","slug":"harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","title":{"rendered":"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Nov.  16, 2020  (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020.<\/p>\n<p>The pre-recorded fireside chat will be accessible beginning November 23, 2020 in the Investors section of Harpoon Therapeutics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d6UD4DbHub5h5JZ-3GJtjZhlA0QePcx93L2iCGXkoT61HUbPx-Dhc1n3VdD20PA4fEH_YX9NA9ESi7L-ABTk1g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.harpoontx.com<\/a>. The recording will be available on the website through December 3, 2020.<\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong>Harpoon<\/strong><br \/>\n        <strong> Therapeutics<\/strong>\n      <\/p>\n<p>Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body\u2019s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient\u2019s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC<sup>\u00ae<\/sup>) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1\/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1\/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1\/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase 1\/2 trial in the fourth quarter of 2020. Harpoon has also developed a proprietary ProTriTAC<sup>TM<\/sup> platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d6UD4DbHub5h5JZ-3GJtje1-nzODmMejl9za887TOMxyDZ7UxbuPuyHUZj6FRNm9tj1ZoGqnh1bFy_Gh5hAoJEW4pzS9mut9j_-F1t8TCylFPgcicLoKt9X86G5UASIk0sgk8ARH-SmokL1YqsNnfAzrlo9q0rPlFLJrH4myo2pTBy8ED8TstfLgMCJ92V5wHo7tGuQtG19yg4s2fgzT9qW_Qy6CaIx3X1UODS9usXc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.harpoontx.com<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ctarget,\u201d \u201cestimate,\u201d \u201cintend\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics\u2019 expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics\u2019 clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, the timing of development milestones for product candidates, and the anticipated potential impacts to Harpoon Therapeutics\u2019 business from the ongoing COVID-19 pandemic. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics\u2019 actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics\u2019 filings with the U.S. Securities and Exchange Commission, including the \u201cRisk Factors\u201d sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p>Harpoon Therapeutics, Inc.<br \/>Georgia Erbez<br \/>Chief Financial Officer<br \/>650-443-7400<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6P_9scAPYV9nzLug_YJsjsz3Ns3r9lrh1owv-nuGaf-r575riSdk7emi8I-dMHoho0j73fphDrIcdL4zxr1J7qKuh9NmdiUyCC_1bdW4MAQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@harpoontx.com<\/a><\/p>\n<p>Westwicke ICR<br \/>Robert H. Uhl<br \/>Managing Director<br \/>858-356-5932 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TAzzQtY8p0B43YXwrfo2NuUsz7dC9BEGR3DYc0Hy2BDAJlygm-UvUtOqhNhhgM-L4eCbBdPHflEd7EOBHyqaF1uLqU6aS2215rn4RuIsWfs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">robert.uhl@westwicke.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9842b951-1c20-4284-8118-c2fb5eafeaf6\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020. The pre-recorded fireside chat will be accessible beginning November 23, 2020 in the Investors section of Harpoon Therapeutics\u2019 website at www.harpoontx.com. The recording will be available on the website through December 3, 2020. About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-381502","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020. The pre-recorded fireside chat will be accessible beginning November 23, 2020 in the Investors section of Harpoon Therapeutics\u2019 website at www.harpoontx.com. The recording will be available on the website through December 3, 2020. About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness &hellip; Continue reading &quot;Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T12:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference\",\"datePublished\":\"2020-11-16T12:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"},\"wordCount\":654,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\",\"name\":\"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=\",\"datePublished\":\"2020-11-16T12:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020. The pre-recorded fireside chat will be accessible beginning November 23, 2020 in the Investors section of Harpoon Therapeutics\u2019 website at www.harpoontx.com. The recording will be available on the website through December 3, 2020. About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness &hellip; Continue reading \"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T12:33:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference","datePublished":"2020-11-16T12:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/"},"wordCount":654,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","name":"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=","datePublished":"2020-11-16T12:33:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTk0OSMzODI2ODE3IzIxMjU4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=381502"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381502\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=381502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=381502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=381502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}